A Cell Cycle Regulator Potentially Involved in Genesis of Many Tumor Types
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
A putative tumor suppressor locus on the short arm of human chromosome 9 has been localized to a region of less than 40 kilobases by means of homozygous deletions in melanoma cell lines. This region contained a gene, Multiple Tumor Suppressor 1 (MTS1), that encodes a previously identified inhibitor (p16) of cyclin-dependent kinase 4. MTS1 was homozygously deleted at high frequency in cell lines derived from tumors of lung, breast, brain, bone, skin, bladder, kidney, ovary, and lymphocyte. Melanoma cell lines that carried at least one copy of MTS1 frequently carried nonsense, missense, or frameshift mutations in the gene. These findings suggest that MTS1 mutations are involved in tumor formation in a wide range of tissues.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Within months of its discovery, the INK4a (CDKN2A) and the genetically linked INK4b gene (CDKN2B) (36) were implicated in a reverse genetic screen to play tumor suppressive roles in familial melanoma (37).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [37]
Citations
Cites
Molecular Cloning: A Laboratory Manual
Sambrook, J., Fritsch, E., & Maniatis, T. (1989) · UCLA - Biblioteca de Ciencias de la Salud · Cited by 133,589
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
p21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,368
A novel cyclin encoded by a bcl1-linked candidate oncogene
Motokura, T., Bloom, T., Kim, H. G., Jüppner., H., Ruderman, J. V., Kronenberg, H. M., & Arnold, A. (1991) · Nature · doi:10.1038/350512a0 · Cited by 1,265
Functional interactions of the retinoblastoma protein with mammalian D-type cyclins
Ewen, M. E., Sluss, H. K., Sherr, C. J., Matsushime, H., Kato, J.-Y., & Livingston, D. M. (1993) · Cell · doi:10.1016/0092-8674(93)90136-e · Cited by 1,010
Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit
Gu, Y., Turck, C. W., & Morgan, D. O. (1993) · Nature · doi:10.1038/366707a0 · Cited by 764
p53: At the Crossroads of Molecular Carcinogenesis and Risk Sssessment
Harris, C. C. (1993) · Science · doi:10.1126/science.8266092 · Cited by 475
PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma.
Rosenberg, C. L., Wong, E., Petty, E. M., Bale, A. E., Tsujimoto, Y., Harris, N. L., & Arnold, A. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.21.9638 · Cited by 432
Research works printed but not linked: 1
- Weaver-Feldhaus, J., Proceedings of the National Academy of Sciences of the United States of America 91: 7563 (1994).
Cited by
Items 801–900 of 1,005
Low Frequency of p16INK4a Alterations in Insulinomas
Bartsch, D. K., Kersting, M., Wild, A., Ramaswamy, A., Gerdes, B., Schuermann, M., Simon, B., & Rothmund, Μ. (2000) · Digestion · doi:10.1159/000007810 · Cited by 69
Genome-wide analyses on loss of heterozygosity in hepatocellular carcinoma in Southern China
Li, S., Wang, H., Li, J.-Q., Zhang, C., Feng, Q.-S., Huang, P., Yu, X.-J., Huang, L.-X., Liang, Q.-W., & Zeng, Y.-X. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00047-2 · Cited by 65
p16INK4a promoter methylation and protein expression in breast fibroadenoma and carcinoma
Vinci, A. D., Perdelli, L., Banelli, B., Salvi, S., Casciano, I., Gelvi, I., Allemanni, G., Margallo, E., Gatteschi, B., & Romani, M. (2004) · International Journal of Cancer · doi:10.1002/ijc.20771 · Cited by 71
Viruses – seeking and destroying the tumor program
O’Shea, C. C. (2005) · Oncogene · doi:10.1038/sj.onc.1209047 · Cited by 73
“For example, loss of p16 functions, through mutations, promoter hypermethylation or epigenetic silencing (Kamb et al., 1994; Nobori et al., 1994), or upregulation of cyclin/cdk expression, are frequent lesions.”
BackgroundZi, X., & Agarwal, R. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1398 · Cited by 69
Defective Folding of Mutant p16INK4 Proteins Encoded by Tumor-derived Alleles
Zhang, B., & Peng, Z.-Y. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.46.28734 · Cited by 64
Biological and molecular basis of human breast cancer
Russo, J. (1998) · Frontiers in bioscience · doi:10.2741/a335 · Cited by 79
Loss of heterozygosity and microsatellite instability in hepatocellular carcinoma in Taiwan
Sheu, J., Lin, Y.-W., Chou, H.-C., Huang, G.-T., Lee, M., Lin, Y.-H., Huang, S.-Y., Chen, C., Wang, J.-T., Lee, P.-H., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690380 · Cited by 64
“…1998 Accepted 17 November 1998 Correspondence to: J-C Sheu n in ). is al o. d. ing es 2; ye es e, - 2). ne 2). ces c- al ur 1, BRCA2 and DPC4 genes (Kamb et al, 1994; Miki et al, 19 Linardopoulos et al, 1995; Wooster et al, 1995; Hahn et al, 19 Identification of subtle genetic changes indicative…”
BackgroundFlaherty, K. T. (2012) · Annual Review of Medicine · doi:10.1146/annurev-med-050410-105655 · Cited by 64
Targets for molecular therapy of skin cancer
Green, C. L., & Khavari, P. A. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2003.11.007 · Cited by 64
The p15INK4b/p16INK4a/RB1 Pathway Is Frequently Deregulated in Human Pituitary Adenomas
Ogino, A., Yoshino, A., Katayama, Y., Watanabe, T., Ota, T., Komine, C., Yokoyama, T., & Fukushima, T. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/64.5.398 · Cited by 63
Cell Cycle Dysregulation in Pituitary Oncogenesis
Musat, M., Vax, V., Borboli, N., Gueorguiev, M., Bonner, S., Korbonits, M., & Grossman, A. B. (2004) · KARGER eBooks · doi:10.1159/000079037 · Cited by 70
Invited Review: Effect of oxygen deprivation on cell cycle activity: a profile of delay and arrest
Douglas, R. M., & Haddad, G. G. (2003) · Journal of Applied Physiology · doi:10.1152/japplphysiol.01029.2002 · Cited by 72
Yasui, W., Kuniyasu, H., Yokozaki, H., Semba, S., Tahara, E., & Shimamoto, F. (1996) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/bf00196815 · Cited by 67
Soder, A. I., Hopman, A. H. N., Ramaekers, F. C. S., Conradt, C., & Bosch, F. X. (1995) · PubMed · Cited by 63
Cayuela, J., Gardie, B., & Sigaux, F. (1997) · Blood · doi:10.1182/blood.v90.9.3720 · Cited by 72
AnEWS/ERG fusion with a truncated N-terminal domain ofEWS in a Ewing's tumor
Peter, M., Mugneret, F., Aurias, A., Thomas, G. D., Magdelénat, H., & Delattre, O. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960729)67:3<339::aid-ijc6>3.0.co;2-s · Cited by 29
K-ras and p16INK4Aalterations in sputum of NSCLC patients and in heavy asymptomatic chronic smokers
Destro, A., Bianchi, P. P., Alloisio, M., Laghi, L., Gioia, S. D., Malesci, A., Cariboni, U., Gribaudi, G., Bulfamante, G., Marchetti, A., et al. (2003) · Lung Cancer · doi:10.1016/j.lungcan.2003.10.002 · Cited by 66
Haddad, M. M., Xu, W., Schwahn, D. J., Liao, F., & Medrano, E. E. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4688 · Cited by 69
Tumours of familial origin in the head and neck
Suarez, C. M., Rodrigo, J. P., Ferlito, A., Cabanillas, R., Shaha, A. R., & Rinaldo, A. (2006) · Oral Oncology · doi:10.1016/j.oraloncology.2006.03.002 · Cited by 79
Souza, R. F., Morales, C. P., & Spechler, S. J. (2001) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2001.01046.x · Cited by 76
Duncan, L. D., Winkler, M. R., Carlson, E. R., Heidel, R. E., Kang, E., & Webb, D. V. (2013) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2013.02.019 · Cited by 66
Sherr, C. J. (2001) · Cell · doi:10.1016/s0092-8674(01)00486-x · Cited by 78
Sandhu, C., Donovan, J. C. H., Bhattacharya, N., Stampfer, M. R., Worland, P. J., & Slingerland, J. M. (2000) · Oncogene · doi:10.1038/sj.onc.1203908 · Cited by 68
“Moreover, many human tumors and immortal cell lines show an absence of p16 protein (Hunter and Pines, 1994; Kamb et al., 1994) and embryonic ®broblasts from p16 knockout mice undergo spontaneous immortalization (Serrano et al., 1996).”
Backgroundp16INK4a inactivation is not frequent in uncultured sporadic primary cutaneous melanoma
Fujimoto, A., Morita, R., Hatta, N., Takehara, K., & Takata, M. (1999) · Oncogene · doi:10.1038/sj.onc.1202803 · Cited by 67
“…kinase 4 and 6, because this gene is frequently mutated or homozygously deleted in melanoma-derived cell lines (Kamb et al., 1994a; Liu et al., 1995; Nobori et al., 1994) and is mutated in the germline of a subset of familial melanoma patients (Hussussian et al., 1994; Kamb et al., 1994b).”
BackgroundSánchez‐Aguilera, A., Sánchez‐Beato, M., García, J. F., Priéto, I., Pollán, M., & Piris, M. A. (2002) · Blood · doi:10.1182/blood.v99.4.1411 · Cited by 66
Harvat, B. L., & Jetten, A. M. (1996) · PubMed · Cited by 76
Association Between INK4a-ARF and p53 Mutations in Skin Carcinomas of Xeroderma Pigmentosum Patients
Soufir, N., Daya-Grosjean, L., de La Salmonière, P., Moles, J. P., Dubertret, L., Sarasin, A., & Basset-Seguin, N. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.22.1841 · Cited by 73
(1998) · doi:10.1002/(sici)1098-1004(1998)11:6
Deletion of cyclin-dependent kinase 4 inhibitor genes P15 and P16 in non-Hodgkin's lymphoma
Koduru, P., Zariwala, M. G., Soni, M., Gong, J., Xiong, Y., & Broome, J. (1995) · Blood · doi:10.1182/blood.v86.8.2900.2900 · Cited by 68
Yang, X., Jin, G., Nakao, Y., Rahimtula, M., Pater, M. M., & Pater, A. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960126)65:3<275::aid-ijc1>3.0.co;2-x · Cited by 50
Hiroyasu, M., Ozeki, M., Kohda, H., Echizenya, M., Tanaka, T., Hiai, H., & Toyokuni, S. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64860-2 · Cited by 61
Kadekaro, A. L. (2006) · Frontiers in Bioscience · doi:10.2741/1958 · Cited by 61
Mern, D. S., Hasskarl, J., & Burwinkel, B. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605897 · Cited by 66
“Previously, we have shown that Id1/3-PA7 regulates the expression of CDKN1A and CDKN1B in a dose-dependent manner in breast cancer cells MCF-7 and MDAMB-231, which contain the homozygous deletions of the gene CDKN2A (Kamb et al, 1994).”
BackgroundSecond malignancies in prostate carcinoma patients after radiotherapy compared with surgery
Brenner, D. J., Curtis, R. E., Hall, E. J., & Ron, E. (2000) · Cancer · doi:10.1002/(sici)1097-0142(20000115)88:2<398::aid-cncr22>3.0.co;2-v · Cited by 618
Germline melanoma susceptibility and prognostic genes: A review of the literature
Ward, K. A., Lazovich, D., & Hordinsky, M. K. (2012) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2012.02.042 · Cited by 77
Giefing, M., Zemke, N., Brauze, D., Kostrzewska‐Poczekaj, M., Luczak, M., Szaumkessel, M., Pelinska, K., Kiwerska, K., Tönnies, H., Grenman, R., et al. (2011) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20840 · Cited by 61
“Several TSG, including CDKN2A, PTEN, SMARCB1, RB1, and TNFAIP3, were thus identified by the delineation of homozygous deletions (Kamb et al., 1994; Li et al., 1997; Versteege et al., 1998; Schmitz et al., 2009).”
BackgroundOhtani, N., Yamakoshi, K., Takahashi, A., & Hara, E. (2010) · Cell Division · doi:10.1186/1747-1028-5-1 · Cited by 62
Biallelic Deletions in INK4 in Cutaneous Melanoma Are Common and Associated with Decreased Survival
Grafström, E., Egyházi, S., Ringborg, U., Hansson, J., & Platz, A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1731 · Cited by 61
Breuer, R. H. J., Snijders, P. J. F., Sutedja, G., Sewalt, R. G. A. B., Otte, A. P., Postmus, P. E., Meijer, C. J. L. M., Raaphorst, F. M., & Smit, E. F. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2004.11.026 · Cited by 62
Pineau, P., Marchio, A., Nagamori, S., Seki, S., Tiollais, P., & Dejean, A. (2003) · Hepatology · doi:10.1053/jhep.2003.50138 · Cited by 61
Rulyak, S. J., Brentnall, T. A., Lynch, H. T., & Austin, M. A. (2003) · Cancer · doi:10.1002/cncr.11562 · Cited by 65
Hundahl, S. A., Fleming, I. D., Fremgen, A. M., & Menck, H. R. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981215)83:12<2638::aid-cncr31>3.0.co;2-1 · Cited by 1,836
Chaudru, V., Laud, K., Avril, M.-F., Minière, A., Chompret, A., Bressac-de Paillerets, B., Demenais, F., & The French Familial Melanoma Study Group (2005) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-04-0777 · Cited by 61
Tajiri, T., Liu, X., Thompson, P. M., Tanaka, S., Suita, S., Zhao, H., Maris, J. M., Prendergast, G. C., & Hogarty, M. D. (2003) · PubMed · Cited by 75
Dreyer, M., Borcherding, D. R., Dumont, J. A., Peet, N. P., Tsay, J. T., Wright, P. S., Bitonti, A. J., Shen, J., & Kim, S. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm001043t · Cited by 61
Sabah, M., Cummins, R., Leader, M., & Kay, E. W. (2004) · Modern Pathology · doi:10.1038/modpathol.3800199 · Cited by 70
Goldsmith, E. J., & Cobb, M. H. (1994) · Current Opinion in Structural Biology · doi:10.1016/0959-440x(94)90264-x · Cited by 61
浜田, 邦., Kohno, T., Kawanishi, M., Ohwada, S., & Yokota, J. (1998) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199807)22:3<232::aid-gcc9>3.0.co;2-x · Cited by 67
Biomarkers for Immune Checkpoint Inhibitors in Melanoma
Kitano, S., Nakayama, T., & Yamashita, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00270 · Cited by 72
Identification of Distinct Tumor Subpopulations in Lung Adenocarcinoma via Single-Cell RNA-seq
Min, J.-W., Kim, W. J., Han, J. A., Jung, Y.-J., Kim, K.-T., Park, W.-Y., Lee, H.-O., & Choi, S. S. (2015) · PLOS ONE · doi:10.1371/journal.pone.0135817 · Cited by 60
“It may not be surprising to find cell-cycle genes among the set of genes related to tumor cell subpopulations because cell cycle genes in particular have long been known to play key roles in tumor cell proliferation and tumor progression [44 – 48].”
Down-regulation of Cdk inhibitor p27 in oral squamous cell carcinoma
Kudo, Y., Kitajima, S., Ogawa, I., Miyauchi, M., & Takata, T. (2004) · Oral Oncology · doi:10.1016/j.oraloncology.2004.05.003 · Cited by 66
CDKN2 deletions have no prognostic value in childhood precursor-B acute lymphoblastic leukaemia
van Zutven, L. J. C. M., van Drunen, E., de Bont, J. M., Wattel, M. M., den Boer, M. L., Pieters, R., Hagemeijer, A., Slater, R. M., & Beverloo, H. B. (2005) · Leukemia · doi:10.1038/sj.leu.2403769 · Cited by 60
Functional cloning of a tumor suppressor gene, TSLC1, in human non-small cell lung cancer
Murakami, Y. (2002) · Oncogene · doi:10.1038/sj.onc.1205825 · Cited by 60
“…gene, RB, in 1986 by positional cloning of 13q14, numbers of tumor suppressor genes were identified in hereditary cancers in the late 1980s to early 1990s (Friend et al., 1986; Haber et al., 1990; Xu et al., 1990; Groden et al., 1991; Nishisho et al., 1991; Kamb et al., 1994; Miki et al., 1994).”
BackgroundWang, Y., Zhang, Z., Kastens, E., Lubet, R. A., & You, M. (2003) · PubMed · Cited by 66
Alterations of tumor suppressor gene p16 INK4a in pancreatic ductal carcinoma
Attri, J., Srinivasan, R., Majumdar, S., Radotra, B. D., & Wig, J. D. (2005) · BMC Gastroenterology · doi:10.1186/1471-230x-5-22 · Cited by 74
“In cancers, functional loss of p16INK4a occurs as a consequence of somatic mutations, homozygous and heterozygous deletions [6,7].”
BackgroundNovel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles
Engler, T. A., Furness, K., Malhotra, S., Sánchez-Martínez, C., Shih, C., Xie, W., Zhu, G., Zhou, X., Conner, S. E., Faul, M. M., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00461-x · Cited by 62
HPV infections and immunosuppression
Bavinck, J. B., & Berkhout, R. J. (1997) · Clinics in Dermatology · doi:10.1016/s0738-081x(96)00154-x · Cited by 68
Mutational analysis of CDKN2A genes in patients with squamous cell carcinoma of the skin
Saridaki, Z., Liloglou, T., Zafiropoulos, A., Koumantaki, E., Zoras, O., & Spandidos, D. A. (2003) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2003.05230.x · Cited by 65
Dreyling, M. H., Bohlander, S. K., Adeyanju, M., & Olopade, O. I. (1995) · PubMed · Cited by 68
Levesque, M. A., Katsaros, D., Yu, H., Zola, P., Sismondi, P., Giardina, G., & Diamandis, E. P. (1995) · Cancer · doi:10.1002/1097-0142(19950315)75:6<1367::aid-cncr2820750620>3.0.co;2-z · Cited by 123
Chromosome‐9 loss detected by fluorescence in situ hybridization in bladder cancer
Sauter, G., Moch, H., Carroll, P. R., Kerschmann, R., Mihatsch, M. J., & Waldman, F. M. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640205 · Cited by 59
Genetic and environmental factors in cutaneous malignant melanoma
Paillerets, B. B., Avril, M., Chompret, A., & Démenais, F. (2002) · Biochimie · doi:10.1016/s0300-9084(01)01360-8 · Cited by 60
Progress toward Understanding Vascular Malformations
Breugem, C. C., van der Horst, C. M. A. M., & Hennekam, R. C. M. (2001) · Plastic & Reconstructive Surgery · doi:10.1097/00006534-200105000-00033 · Cited by 63
Mapping of Genetic Deletions on the Long Arm of Chromosome 4 in Human Esophageal Adenocarcinomas
Rumpel, C. A., Powell, S. M., & Moskaluk, C. A. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65386-2 · Cited by 59
Reduced expression of p16 and p27 is correlated with tumour progression in cutaneous melanoma
Sanki, A., Li, W., Colman, M. H., Karim, R. Z., Thompson, J. F., & Scolyer, R. A. (2007) · Pathology · doi:10.1080/00313020701684409 · Cited by 65
“Human p16 is a 156 amino acid protein coded by the CDKN2a (also known as INK4a/ARF) locus at 9p21, and was first identified as a target of deletion in melanoma.(3,13) The CDKN2a locus also encodes the tumour suppressor protein p14 (p19 in the mouse).”
BackgroundLerma, E., Esteller, M., Herman, J. G., & Prat, J. (2002) · Human Pathology · doi:10.1053/hupa.2002.129415 · Cited by 59
Alterations of the cyclin D1/pRb/p16INK4A pathway in multiple myeloma
Krämer, A., Schultheis, B. S., Bergmann, J., Willer, A., Hegenbart, U., Ho, A. D., Goldschmidt, H., & Hehlmann, R. (2002) · Leukemia · doi:10.1038/sj.leu.2402609 · Cited by 64
Incidence of germ‐line p53 mutations in patients with gliomas
Li, Y., Sanson, M., Hoang‐Xuan, K., Delattre, J., Poisson, M., Thomas, G. D., & Hamelin, R. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640606 · Cited by 60
Priming in the brain, an immunologically privileged organ, elicits anti-tumor immunity
Fathallah‐Shaykh, H. M., Gao, W., Cho, M., & Herrera, M. A. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980119)75:2<217::aid-ijc9>3.0.co;2-x · Cited by 36
Gombart, A., Roberta Morosetti, A., Cw, M., Jw, S., & Koeffler, H. (1995) · Blood · doi:10.1182/blood.v86.4.1534.bloodjournal8641534 · Cited by 62
Sarkar, S., Jülicher, K., Burger, M. S., Della-Valle, V., Larsen, C., Yeager, T. R., Grossman, T. B., Nickells, R. W., Protzel, C., Jarrard, D. F., et al. (2000) · PubMed · Cited by 65
The functional relevance of somatic synonymous mutations in melanoma and other cancers
Gotea, V., Gartner, J. J., Qutob, N., Elnitski, L. L., & Samuels, Y. (2015) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12413 · Cited by 64
Cutaneous Melanoma in Childhood and Adolescence Shows Frequent Loss of INK4A and Gain of KIT
Daniotti, M., Ferrari, A., Frigerio, S., Casieri, P., Miselli, F., Zucca, E., Collini, P., Torre, G. D., Manoukian, S., Peissel, B., et al. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.422 · Cited by 63
Chen, L., Huang, H., Zhang, W., Ding, F., Fan, Z., & Zeng, Z. (2019) · Medical Science Monitor · doi:10.12659/msm.917058 · Cited by 58
Kiyokawa, N., Lee, E. K., Karunagaran, D., Lin, S.-Y., & Hung, M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.30.18656 · Cited by 59
Molecular Pathology of Non-Small-Cell Lung Cancer
Breuer, R. H. J., Postmus, P. E., & Smit, E. F. (2005) · Respiration · doi:10.1159/000085376 · Cited by 67
Masayesva, B. G., Ha, P. K., Garrett-Mayer, E. S., Pilkington, T., Mao, R., Pevsner, J., Speed, T. J., Benoit, N. E., Moon, C., Sidransky, D., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400027101 · Cited by 68
Mælandsmo, G. M., Holm, R., Fodstad, Ø., Kerbel, R. S., & Flørenes, V. A. (1996) · Europe PMC (PubMed Central) · Cited by 62
Aberrancies in signal transduction and cell cycle related events in Alzheimer’s disease
Arendt, T., Holzer, M., Gärtner, U., & Brückner, M. K. (1998) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-7508-8_14 · Cited by 60
Platz, A., Ringborg, U. K., & Hansson, J. (2000) · Seminars in Cancer Biology · doi:10.1006/scbi.2000.0149 · Cited by 63
Assessment of cell proliferation in pathology—what next?
Hall, P. A., & Coates, P. J. (1995) · Histopathology · doi:10.1111/j.1365-2559.1995.tb00639.x · Cited by 67
Cavé, H., Gérard, B., Martin, E., Guidal, C., Devaux, I., Weissenbach, J., Élion, J., VILMER, E., & Grandchamp, B. (1995) · Blood · doi:10.1182/blood.v86.10.3869.bloodjournal86103869 · Cited by 61
Infrequent Mutation of p16INK4 in Sporadic Melanoma
Healy, E., Sikkink, S. K., & Rees, J. L. (1996) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12363118 · Cited by 67
Schraml, P., Struckmann, K., Bednar, R., Fu, W., Gasser, T., Wilber, K., Kononen, J., Sauter, G., Mihatsch, M. J., & Moch, H. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64001-1 · Cited by 58
Florl, A. R., Franke, K. H., Niederacher, D., Gerharz, C., Seifert, H., & Schulz, W. A. (2000) · Laboratory Investigation · doi:10.1038/labinvest.3780161 · Cited by 58
“I nactivation of the CDKN2A locus at chromosome9p21 is one of the most frequent genetic changes in human cancers (Kamb et al, 1994).”
BackgroundThe Retinoblastoma Protein Is Required for Ras-Induced Oncogenic Transformation
Williams, J. P., Stewart, T. A., Li, B., Mulloy, R., Dimova, D. K., & Classon, M. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.4.1170-1182.2006 · Cited by 64
“However, in those cases, RB pathway disruption does not involve the direct loss of the pRB protein, but instead involves either loss of the Cdk inhibitor p16, amplification of cyclin D1, or mutation of cdk4 (33, 37 , 39, 61, 72, 79).”
BackgroundThe Physiology of p16INK4A-Mediated G1 Proliferative Arrest
Shapiro, G. I., Edwards, C. D., & Rollins, B. J. (2000) · Cell Biochemistry and Biophysics · doi:10.1385/cbb:33:2:189 · Cited by 63
“In fact, p16INK4A maps to 9p21, a locus commonly lost in a variety of human cancers, which is consistent with the presence of a tumor suppressor gene in the region of loss (17,18).”
González, M., Mateos, M., García‐Sánz, R., Balanzategui, A., López‐Pérez, R., Chillón, C., González, D., Alaejos, I., & Miguel, J. F. S. (2000) · Leukemia · doi:10.1038/sj.leu.2401617 · Cited by 62
Glendening, J. M., Flores, J. F., Walker, G. J., Stone, S., Albino, A. P., & Fountain, J. W. (1995) · PubMed · Cited by 69
Geradts, J., Hruban, R. H., Schutte, M., Kern, S. E., & Maynard, R. (2000) · Applied Immunohistochemistry & Molecular Morphology · doi:10.1097/00129039-200003000-00011 · Cited by 56
Loss of function of p16 gene and prognosis of pulmonary adenocarcinoma
Tanaka, R., Wang, D., Morishita, Y., Inadome, Y., Minami, Y., Iijima, T., Fukai, S., Goya, T., & Noguchi, M. (2004) · Cancer · doi:10.1002/cncr.20827 · Cited by 61
cdk6 Can Shorten G1 Phase Dependent upon the N-terminal INK4 Interaction Domain
Grossel, M. J., Baker, G. L., & Hinds, P. W. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.42.29960 · Cited by 56
Molecular genetic abnormalities in premalignant lung lesions: biological and clinical implications
Nikliński, J., Niklińska, W., Chyczewski, L., Becker, H., & Pluygers, E. (2001) · European Journal of Cancer Prevention · doi:10.1097/00008469-200106000-00004 · Cited by 55
Immunohistochemical detection of CDK4 and 9 16INK4proteins in cutaneous malignant melanoma
WANG, Y.-L., UHARA, H., YAMAZAKI, Y., NIKAIDO, T., & SAIDA, T. (1996) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1996.tb07612.x · Cited by 56
Wani, M. A., Zhu, Q. Z., El-Mahdy, M., & Wani, A. A. (1999) · Carcinogenesis · doi:10.1093/carcin/20.5.765 · Cited by 56
Aryl[a]pyrrolo[3,4-c]carbazoles as selective cyclin D1-CDK4 inhibitors
Sánchez-Martı́nez, C., Shih, C., Faul, M. M., Zhu, G., Paal, M., Somoza, C., Li, T., Kumrich, C. A., Winneroski, L. L., Zhou, X., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00791-1 · Cited by 56
Expression of the retinoblastoma protein in low-grade B-cell lymphoma: relationship to cyclin D1
Zukerberg, L., Benedict, W. F., Arnold, A., Dyson, N. J., Harlow, E. E., & Harris, N. L. (1996) · Blood · doi:10.1182/blood.v88.1.268.268 · Cited by 59
Molecular markers of prognosis in astrocytic tumors
Rasheed, A., Herndon, J. E., Stenzel, T. T., Raetz, J. G. M., Kendelhardt, J., Friedman, H. S., Friedman, A. H., Bigner, D. D., Bigner, S. H., & McLendon, R. E. (2002) · Cancer · doi:10.1002/cncr.10544 · Cited by 60
Cancer burden in the aged: An epidemiologic and demographic overview
Yancik, R. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971001)80:7<1273::aid-cncr13>3.0.co;2-4 · Cited by 473
Metadata
- Authors
- Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H.
- Affiliations
- Myriad Genetics (US)
- Memorial Sloan Kettering Cancer Center (US)
- Cross Cancer Institute (CA)
- National Institutes of Health (US)
- University of Utah (US)
- Venue
- Science
- Published
- 1994-04-15
- Volume
- 264
- Issue
- 5157
- Pages
- 436-440
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1983348452
- Cited by
- 2,751
- References
- 26
- Citations by year
- 2026: 11 · 2025: 8 · 2024: 18 · 2023: 12 · 2022: 22 · 2021: 31 · 2020: 24 · 2019: 23 · 2018: 34 · 2017: 45 · 2016: 20 · 2015: 32 · 2014: 31 · 2013: 44 · 2012: 54
- FWCI
- 115.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p01ca048711-05)
- National Cancer Institute (CA 48711)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- CDKN2A, p16, tumor suppressor, chromosome 9p, homozygous deletion, melanoma cell lines, CDK4, cell cycle regulation, genetic mutations
- MeSH terms
- Base Sequence, Carrier Proteins, Cell Cycle, Chromosomes, Human, Pair 9, Cosmids, Exons, Humans, Introns, Melanoma, Molecular Sequence Data, Mutation, Neoplasms, Proto-Oncogene Proteins, Tumor Cells, Cultured, Genes, Tumor Suppressor, Gene Deletion, Cyclin-Dependent Kinases, Cyclin-Dependent Kinase Inhibitor p16, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.